We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 15, 2020

CDK4/6 Inhibitor–Based Therapy Improves Overall Survival in MBC Subgroups

Journal of the National Cancer Institute


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the National Cancer Institute
Overall Survival of CDK4/6-Inhibitors-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis
J. Natl. Cancer Inst 2020 May 14;[EPub Ahead of Print], F Schettini, F Giudici, M Giuliano, M Cristofanilli, G Arpino, L Del Mastro, F Puglisi, S De Placido, I Paris, P De Placido, S Venturini, M De Laurentis, P Conte, D Juric, A Llombart-Cussac, L Pusztai, A Prat, G Jerusalem, A Di Leo, D Generali

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading